keyword
MENU ▼
Read by QxMD icon Read
search

Rotigotine

keyword
https://www.readbyqxmd.com/read/29916262/a-noninterventional-study-evaluating-the-effectiveness-of-rotigotine-and-levodopa-combination-therapy-in-younger-versus-older-patients-with-parkinson-s-disease
#1
Dirk Woitalla, Antoine Dunac, Ali Safavi, Maria-Gabriella Ceravolo, Juan Carlos Gomez Esteban, Nicola Pavese, Mahnaz Asgharnejad, Lars Joeres, Jan-Christof Schuller, K Ray Chaudhuri
BACKGROUND: PD0013 was a 6-month noninterventional study in clinical practice comparing effectiveness/tolerability of rotigotine+levodopa in younger (<70 years) vs. older (≥70 years) Parkinson's disease (PD) patients. METHODS: Patients previously received levodopa for ≥6 months as monotherapy/in combination with another dopamine-agonist (DA). Primary variable: Unified PD Rating Scale (UPDRS) Part-II change from baseline to end-of-observation-period (EOP)...
June 19, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29909386/transdermal-rotigotine-patch-in-parkinson-s-disease-with-a-history-of-intestinal-operation
#2
Takashi Ogawa, Genko Oyama, Nobutaka Hattori
A 42-year-old Japanese man with a history of small intestine resection and familial Mediterranean fever was referred to our hospital for a second opinion on parkinsonism. At the age of 35, the patient attended a hospital due to impaired left-hand movement and resting tremor. He was previously diagnosed with multiple system atrophy based on the lack of effectiveness of levodopa treatment. With suspicion of malabsorption due to his history of ileostomy, a levodopa challenge test with levodopa intravenous infusion was conducted, and revealed a 65% improvement in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part III...
June 15, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29763930/rotigotine-improves-abnormal-circadian-rhythm-of-blood-pressure-in-parkinson-s-disease
#3
Hisayoshi Oka, Atuso Nakahara, Tadashi Umehara
INTRODUCTION: Cardiovascular autonomic failure is commonly associated with Parkinson's disease (PD), affecting the daily lives of patients. Rotigotine was recently reported not to influence cardiovascular autonomic responses in contrast to other dopaminergic drugs. The effect of rotigotine on daily blood pressure (BP) fluctuations might reflect autonomic failure in patients with PD. METHODS: Twenty-five PD patients who were receiving rotigotine and 12 patients not receiving rotigotine were recruited...
May 15, 2018: European Neurology
https://www.readbyqxmd.com/read/29756335/treatment-of-restless-legs-syndrome-evidence-based-review-and-implications-for-clinical-practice-revised-2017-%C3%A2
#4
REVIEW
Juliane Winkelmann, Richard P Allen, Birgit Högl, Yuichi Inoue, Wolfgang Oertel, Aaro V Salminen, John W Winkelman, Claudia Trenkwalder, Cristina Sampaio
The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious...
May 14, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29681829/dysphagia-causes-symptom-fluctuations-after-oral-l-dopa-treatment-in-a-patient-with-parkinson-disease
#5
Hiromasa Sato, Toshiyuki Yamamoto, Masako Sato, Yoshihiko Furusawa, Miho Murata
Objective: The causes of "delayed-on" and "no-on" phenomena in Parkinson disease (PD) are thought to have some impact on the progress of L-DOPA from the time of ingestion until it reaches the brain and is converted to dopamine. Dysphagia can cause fluctuating symptom expression in L-DOPA therapy for PD. Case Description: A 69-year-old man with PD presented with "delayed-on" and "no-on" phenomena. The patient developed a gait disorder at age 60 years, and he began coughing on his food during breakfast at age 64 years...
January 2018: Case Reports in Neurology
https://www.readbyqxmd.com/read/29668694/the-efficacy-and-tolerability-of-rotigotine-on-patients-with-periodic-limb-movement-in-sleep-a-systematic-review-and-meta-analysis
#6
Meng-Ni Wu, Ping-Tao Tseng, Tien-Yu Chen, Yen-Wen Chen, Li-Min Liou, Pao-Yen Lin, Chung-Yao Hsu
OBJECTIVE: There is still no consensus on the treatment for periodic limb movement in sleep (PLMS). This study aimed to determine the efficacy and tolerability of rotigotine in patients suffering from PLMS. METHODS: Publications listed in PubMed, ScienceDirect, The Cochrane Library, and ClinicalTrials.gov were reviewed to assess the efficacy of rotigotine on PLMS. Analyses of PLMS frequency before and after rotigotine treatments (pre- and post-intervention studies) and PLMS frequency between placebo and rotigotine treatments (placebo-controlled trial studies) were included in our study...
2018: PloS One
https://www.readbyqxmd.com/read/29602660/management-of-treatment-failure-in-restless-legs-syndrome-willis-ekbom-disease
#7
REVIEW
Diego Garcia-Borreguero, Irene Cano-Pumarega, Rafael Marulanda
Dopaminergic drugs have been widely used over the last decades for the treatment of restless legs syndrome (RLS)/Willis-Ekbom disease (WED). While the majority of studies show an initial improvement in symptoms, longer studies and clinical experience show that either treatment efficacy decreases with time, and/or augmentation develops: dopaminergic augmentation has been reported to be the main reason for treatment discontinuation and treatment failure in RLS/WED. The current review discusses the main reasons for treatment failure in RLS/WED and outlines the most recent expert-based strategies to prevent and manage it...
January 9, 2018: Sleep Medicine Reviews
https://www.readbyqxmd.com/read/29563862/caffeine-protects-dopaminergic-neurons-from-dopamine-induced-neurodegeneration-via-synergistic-adenosine-dopamine-d2-like-receptor-interactions-in-transgenic-caenorhabditis-elegans
#8
Rafael V M Manalo, Paul M B Medina
Previous studies have suggested that caffeine reduces the risk of L-DOPA-induced dyskinesia. However, caffeine is also known to promote dopamine signaling, which seemingly contradicts this observed effect. To this end, the study aimed to clarify the mechanism of caffeine neuroprotection in vivo when excess dopamine is present. Transgenic Caenorhabditis elegans (UA57) overproducing dopamine was exposed to caffeine for 7 days and monitored by observing GFP-tagged dopaminergic (DA) neurons via fluorescence microscopy...
2018: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/29520899/pain-in-parkinson-s-disease-facts-and-uncertainties
#9
REVIEW
A Antonini, M Tinazzi, G Abbruzzese, A Berardelli, K R Chaudhuri, G Defazio, J Ferreira, P Martinez-Martin, C Trenkwalder, O Rascol
Pain is one of the most common and troublesome non-motor symptoms of Parkinson's disease (PD). It can appear at any time during the disease and is often present before diagnosis. However, there is little or no consensus on its definition. An expert group of clinicians with relevant research experience met to review the existing evidence and to identify gaps in our understanding leading towards AUTHOR: 'understanding towards' has been changed to 'understanding leading towards'. Please check and confirm that this is appropriate an optimized therapy of pain in PD...
March 9, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29484495/an-observational-study-of-rotigotine-transdermal-patch-and-other-currently-prescribed-therapies-in-patients-with-parkinson-s-disease
#10
Thomas Müller, Eduardo Tolosa, Letitia Badea, Mahnaz Asgharnejad, Frank Grieger, Michael Markowitz, Xavier Nondonfaz, Lars Bauer, Lars Timmermann
Real-world data from large cohorts of patients with Parkinson's disease on the long-term effectiveness of different dopamine-substituting drug therapies are rare. The objective of this study was to obtain information on real-world management of PD with dopamine-substituting drugs. SP0854 (NCT00599339) was a prospective, multicenter, non-interventional, multiple-cohort, post-authorization safety study of rotigotine versus other dopaminergic therapies. The study was also part of a European Medicines Agency risk-management plan for the non-ergoline dopamine agonist rotigotine, focussing on cardiovalvular fibrosis...
February 26, 2018: Journal of Neural Transmission
https://www.readbyqxmd.com/read/29461870/randomized-double-blind-crossover-study-of-the-adhesiveness-of-two-formulations-of-rotigotine-transdermal-patch-in-patients-with-parkinson-s-disease
#11
Jan-Peer Elshoff, Lars Bauer, Nadine Goldammer, Marga Oortgiesen, Hanna Pesch, Lars Timmermann
OBJECTIVE: In patch-based transdermal drug delivery, adhesiveness is critical for safe and effective treatment, especially in Parkinson's disease (PD) where excessive sweating is common. This study compared the adhesiveness of two transdermal patch formulations of rotigotine (improved room temperature-stable [PR2.3.1/Treatment A] and intermediate cold storage product [PR2.1.1/Treatment B]), using the largest patch size (40 cm2 ). METHODS: PD0018 (NCT02230904) was a multicenter, randomized, double-blind, crossover study...
February 20, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29442177/effectiveness-of-rotigotine-plus-intensive-and-goal-based-rehabilitation-versus-rotigotine-alone-in-de-novo-parkinsonian-subjects-a-randomized-controlled-trial-with-18-month-follow-up
#12
D Ferrazzoli, P Ortelli, G Riboldazzi, R Maestri, G Frazzitta
BACKGROUND: Dopamine Replacement Therapy (DRT) represents the most effective treatment for Parkinson's disease (PD). Nevertheless, several symptoms are unresponsive to treatment and its long-term use leads to serious side effects. To optimize the pharmacological management of PD, dopamine-agonists are often prescribed to "de-novo" patients. Moreover, several studies have shown the effectiveness and the synergic effect of rehabilitation in treating PD. OBJECTIVE: To evaluate the synergism between DRT and rehabilitation in treating PD, by investigating the short and the long-term effectiveness of a multidisciplinary, intensive and goal-based rehabilitation treatment (MIRT) in a group of patients treated with Rotigotine...
April 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29391788/lactoferrin-modified-rotigotine-nanoparticles-for-enhanced-nose-to-brain-delivery-lesa-ms-ms-based-drug-biodistribution-pharmacodynamics-and-neuroprotective-effects
#13
Xiuju Yan, Lixiao Xu, Chenchen Bi, Dongyu Duan, Liuxiang Chu, Xin Yu, Zimei Wu, Aiping Wang, Kaoxiang Sun
Introduction: Efficient delivery of rotigotine into the brain is crucial for obtaining maximum therapeutic efficacy for Parkinson's disease (PD). Therefore, in the present study, we prepared lactoferrin-modified rotigotine nanoparticles (Lf-R-NPs) and studied their biodistribution, pharmacodynamics, and neuroprotective effects following nose-to-brain delivery in the rat 6-hydroxydopamine model of PD. Materials and methods: The biodistribution of rotigotine nanoparticles (R-NPs) and Lf-R-NPs after intranasal administration was assessed by liquid extraction surface analysis coupled with tandem mass spectrometry...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29339630/comparison-of-the-efficacy-of-different-drugs-on-non-motor-symptoms-of-parkinson-s-disease-a-network-meta-analysis
#14
Bao-Dong Li, Jing-Jun Cui, Jia Song, Ce Qi, Pei-Feng Ma, Ya-Rong Wang, Jing Bai
BACKGROUND/AIMS: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson's disease (PD). METHODS: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD...
2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29332198/drug-delivery-and-transport-into-the-central-circulation-an-example-of-zero-order-in-vivo-absorption-of-rotigotine-from-a-transdermal-patch-formulation
#15
Willi Cawello, Marina Braun, Jens-Otto Andreas
BACKGROUND AND OBJECTIVE: Pharmacokinetic studies using deconvolution methods and non-compartmental analysis to model clinical absorption of drugs are not well represented in the literature. The purpose of this research was (1) to define the system of equations for description of rotigotine (a dopamine receptor agonist delivered via a transdermal patch) absorption based on a pharmacokinetic model and (2) to describe the kinetics of rotigotine disposition after single and multiple dosing...
January 13, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29249180/the-effects-of-transdermal-rotigotine-on-non-motor-symptoms-of-parkinson-s-disease-a-multicentre-observational-retrospective-post-marketing-study
#16
Francesc Valldeoriola, Antonio Salvador, José Maria Gómez-Arguelles, José Marey, Miguel Moya, Ángel Ayuga, Francisco Ramírez
AIM: This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease. MATERIALS AND METHODS: The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months...
April 2018: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29221778/long-term-treatment-with-dopamine-d3-receptor-agonists-induces-a-behavioral-switch-that-can-be-rescued-by-blocking-the-dopamine-d1-receptor
#17
Mai-Lynne Dinkins, Perrine Lallemand, Stefan Clemens
Restless legs syndrome (RLS) is commonly treated with the dopamine agonists pramipexole, and rotigotine, which target the inhibitory dopamine receptor subtype D3R. While initially highly effective, these compounds lose their efficacy in treating RLS over time, and long-term therapy regularly leads to a worsening of the symptoms (augmentation). This dopamine agonist-induced augmentation has become a prime concern in the treatment of RLS, and while alternate therapies are being proposed, the mechanisms leading to augmentation remain opaque...
December 2017: Sleep Medicine
https://www.readbyqxmd.com/read/29198453/effects-of-rotigotine-on-clinical-symptoms-quality-of-life-and-sleep-hygiene-adequacy-in-haemodialysis-associated-restless-legs-syndrome
#18
Vicent Esteve, Jose Carneiro, Gabriel Salazar, Mónica Pou, Irati Tapia, Miquel Fulquet, Verónica Duarte, Anna Saurina, Fátima Moreno, Manel Ramírez de Arellano
BACKGROUND: Restless legs syndrome (RLS) is a neurological disorder characterised by bothersome symptoms associated with impaired quality of life and sleep hygiene. Rotigotine is a novel therapeutic alternative, although few studies have been published in patients on haemodialysis (HD) with RLS treated with rotigotine. OBJECTIVES: 1.- To establish the prevalence of RLS in our HD unit. 2.- To evaluate the efficacy and safety profile of rotigotine and its effect on symptoms, quality of life and sleep hygiene in our HD population with RLS...
January 2018: Nefrología: Publicación Oficial de la Sociedad Española Nefrologia
https://www.readbyqxmd.com/read/29164312/efficacy-and-safety-of-rotigotine-in-elderly-patients-with-parkinson-s-disease-in-comparison-with-the-non-elderly-a-post-hoc-analysis-of-randomized-double-blind-placebo-controlled-trials
#19
Masahiro Nomoto, Hirotaka Iwaki, Hiroyuki Kondo, Masaya Sakurai
Rotigotine-a non-ergot dopamine agonist-has two advantages; it can stimulate all dopamine receptors (D1-D5) like innate dopamine, and its transdermal administration provides continuous dopaminergic stimulation. The age of the patient impacts the effect and adverse events of anti-parkinsonian treatment. We conducted a post hoc analysis on three randomized, double-blind, placebo-controlled trials performed in Japan to clarify the difference of anti-parkinsonian treatment in elderly and non-elderly patients. Data from two combination therapy trials (with levodopa) in advanced stage Parkinson's disease patients and one monotherapy trial in early stage patients were pooled and grouped by age (non-elderly aged < 70, elderly aged 70 +)...
February 2018: Journal of Neurology
https://www.readbyqxmd.com/read/28993209/rotigotine-a-dopamine-receptor-agonist-increased-bdnf-protein-levels-in-the-rat-cortex-and-hippocampus
#20
Naoki Adachi, Aya Yoshimura, Shuichi Chiba, Shintaro Ogawa, Hiroshi Kunugi
Brain-derived neurotrophic factor (BDNF) critically controls the fate and function of the neuronal network and has received much attention as a target of many brain diseases. Dopaminergic system dysfunction has also been implicated in a variety of neuropsychiatric diseases. Rotigotine, a non-ergot dopamine receptor agonist, is used in the treatment of Parkinson's disease and restless legs syndrome. To investigate the effects of rotigotine on neuronal functions both in vivo and in vitro, rats and primary cortical neurons were administered rotigotine, and the mRNA and protein expression levels of BDNF, its receptor TrkB and downstream signaling molecules, and synaptic proteins were determined...
January 1, 2018: Neuroscience Letters
keyword
keyword
56686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"